PepGen (PEPG) said Tuesday it has made a voluntary decision to temporarily pause its CONNECT2-EDO51 phase 2 study of PGN-EDO51 in Duchenne muscular dystrophy patients until it can review results from an ongoing study.
Pausing the study until PepGen is able to review results from the 10 mg/kg group in the phase 2 CONNECT1-EDO51 trial "will allow us to gather additional safety data, assess the impact of this dose of PGN-EDO51 on dystrophin levels, and potentially improve the design of CONNECT2," said James McArthur, CEO of PepGen.
PepGen shares were down 11% in premarket activity Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.